I'm holding. Final questions posed by notifying body re CE mark...

I'm holding. Final questions posed by notifying body re CE mark were answered late Nov. while there are no final questions, a go or whoa answer should be in early this year. CEO has toned down language (learning from past mistakes?) and has stated that shareholders shouldn't get too excited as signigicant sales falling off CE mark will not happen overnight. But the CE mark wil remove the key uncertainty that has pissed-off the punters.

Having known a pancreatic cancer sufferer, there's significant potential for anything that extends lifespan and quality of life to make an impact (if proven safe, and somewhat effective). The clinical trials to date still point to Oncosil ticking these boxes. Adoption and recommendation by clinicians is another separate challenge and a key pre-cursor to purchase by individuals/insurers.

I nearly bailed recently but went back to the initial studies and checked out all the staff on board. There is a decent team behind Oncosil that would not have jumped from their previous roles if not confident in potential of the 'device'. I also clarified in my own mind that the 'device' itself is not the delivery method/tool but the radioactive particles suspended in silicon...